Park Ha Biological Securities Class Action
Analysis based on 154 articles · First reported Jul 28, 2026 · Last updated Sep 21, 2026
The litigation reinforces severe reputational and legal risk for Park Ha, whose shares already collapsed roughly 93% in a single session, and keeps the stock under pressure with potential damages and governance scrutiny. For the broader market, the case is a contained, company-specific event that mainly affects investor confidence in low-float, promotion-driven small-cap IPOs rather than systemic market conditions.
Multiple US investor-rights law firms have filed and are publicizing a securities class action against Park Ha Biological Technology Company (Nasdaq: BYAH) and certain of its officers. The complaint, filed on behalf of purchasers of Park Ha securities between December 27, 2024 and July 8, 2025, alleges that the company made materially false and misleading statements and failed to disclose that it was the subject of a fraudulent stock promotion and market manipulation scheme involving social-media-based misinformation and individuals impersonating financial professionals. According to the complaint, Park Ha's IPO was intentionally structured with an extremely low public float, facilitating the alleged manipulation. The stock reportedly rose from its $4.00 IPO price on December 27, 2024 to an intraday high of $41.49 on July 7, 2025, then fell approximately 93% on July 8, 2025, closing at $2.99 and erasing more than $1 billion in market capitalization. Promoters allegedly touted a rumored partnership with L Oréal for a sensitive-skin product line, which the complaint says had no basis. Bronstein, Gewirtz & Grossman, Pomerantz LLP, The Rosen Law Firm, and Levi & Korsinsky (via SueWallSt) are soliciting investors, with a lead plaintiff deadline of September 28, 2026 (September 21, 2026 per Bronstein).
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard